SEC Form 4 · accession 0001193125-26-343079
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey G. Lamothe
Officer — President and CEO · Director
Period of report
Aug 6, 2026
Accepted (ET)
Aug 10, 2026 · 9:38 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001671584
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 6, 2026 | M | 961 | — | A | 961 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Aug 6, 2026 | M | 961 | D | — | — | Common Stock | 961 | 0 | D |
Explanation of responses
- F1Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
- F2On August 6, 2025, the reporting person was granted 17,300 (961 post-split) RSUs, vesting on the first anniversary of the date of grant.